JHS Svendgaard Laboratories Ltd Falls to 52-Week Low of Rs.9.17

Stock Performance and Market Context

The stock has been on a downward trajectory, falling for three consecutive days and registering a cumulative loss of 4.46% during this period. Today’s decline of 0.84% further extended its underperformance, with the stock lagging the FMCG sector by 1.62%. This movement places JHS Svendgaard Laboratories Ltd well below its key moving averages, trading beneath the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling sustained bearish momentum.

In contrast, the broader market has shown resilience. The Sensex, after a negative start, recovered to close marginally higher by 0.06% at 85,811.65 points, just 0.4% shy of its 52-week high of 86,159.02. The index is supported by bullish technical indicators, trading above its 50-day moving average, which itself is positioned above the 200-day moving average. Mid-cap stocks have also contributed positively, with the BSE Mid Cap index gaining 0.15% today.

Long-Term Performance and Valuation Metrics

Over the past year, JHS Svendgaard Laboratories Ltd has delivered a negative return of 57.24%, a stark contrast to the Sensex’s 8.32% gain over the same period. The stock’s 52-week high was Rs.22.46, underscoring the extent of the decline to the current low of Rs.9.17. This sustained underperformance has been consistent over the last three years, with the stock lagging the BSE500 index in each annual period.

Valuation-wise, the stock is trading at levels considered risky relative to its historical averages. Despite a 56.5% increase in profits over the past year, the company’s financial health remains a concern. The operating profit compound annual growth rate (CAGR) over the last five years has been negative at -18.37%, reflecting deteriorating profitability trends.

Financial Health and Profitability Concerns

The company’s ability to service its debt is notably weak, with an average EBIT to interest ratio of -8.32, indicating that earnings before interest and tax are insufficient to cover interest expenses. This has contributed to reported losses and a negative return on capital employed (ROCE), signalling challenges in generating adequate returns from invested capital.

Additionally, the company reported flat financial results in the quarter ending September 2025, which did not provide any uplift to investor sentiment. The negative EBITDA further emphasises the precarious financial position, with the stock’s risk profile elevated compared to its historical valuation norms.

Shareholding Pattern and Market Position

JHS Svendgaard Laboratories Ltd’s majority shareholding is held by non-institutional investors, which may influence liquidity and trading dynamics. The company operates within the FMCG sector, a space generally characterised by steady demand, but the stock’s performance has diverged significantly from sector trends.

Summary of Key Metrics

To summarise, JHS Svendgaard Laboratories Ltd currently holds a Mojo Score of 12.0 with a Mojo Grade of Strong Sell, upgraded from Sell on 13 Nov 2024. The company’s market capitalisation grade stands at 4, reflecting its micro-cap status. The stock’s recent price action and fundamental indicators highlight ongoing challenges in profitability and valuation.

While the broader market and FMCG sector have shown resilience, JHS Svendgaard Laboratories Ltd’s stock remains under pressure, trading near its lowest levels in the past year. The divergence from benchmark indices and sector performance underscores the stock’s current position within the market landscape.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Saving Now →